Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA

Keppens, Cleo, Dequeker, Elisabeth M. C., Patton, Simon J., Normanno, Nicola, Fenizia, Francesca, Butler, Rachel, Cheetham, Melanie, Fairley, Jennifer A., Williams, Hannah, Hall, Jacqueline A., Schuuring, Ed and Deans, Zandra C. 2018. International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA. BMC Cancer 18 (804) 10.1186/s12885-018-4694-x

[thumbnail of BUTLER, Rachel - International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA.pdf]
Preview
PDF - Published Version
Available under License Creative Commons Attribution.

Download (546kB) | Preview

Abstract

Background Molecular analysis of circulating tumour DNA (ctDNA) is becoming increasingly important in clinical treatment decisions. A pilot External Quality Assessment (EQA) scheme for ctDNA analysis was organized by four European EQA providers under the umbrella organization IQN Path, in order to investigate the feasibility of delivering an EQA to assess the detection of clinically relevant variants in plasma circulating cell-free DNA (cfDNA) and to analyze reporting formats. Methods Thirty-two experienced laboratories received 5 samples for EGFR mutation analysis and/or 5 samples for KRAS and NRAS mutation analysis. Samples were artificially manufactured to contain 3 mL of human plasma with 20 ng/mL of fragmented ctDNA and variants at allelic frequencies of 1 and 5%. Results The scheme error rate was 20.1%. Higher error rates were observed for RAS testing when compared to EGFR analysis, for allelic frequencies of 1% compared to 5%, and for cases including 2 different variants. The reports over-interpreted wild-type results and frequently failed to comment on the amount of cfDNA extracted. Conclusions The pilot scheme demonstrated the feasibility of delivering a ctDNA EQA scheme and the need for such a scheme due to high error rates in detecting low frequency clinically relevant variants. Recommendations to improve reporting of cfDNA are provided.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Medicine
Publisher: BioMed Central
ISSN: 1471-2407
Date of First Compliant Deposit: 12 October 2018
Date of Acceptance: 25 July 2018
Last Modified: 05 May 2023 11:06
URI: https://orca.cardiff.ac.uk/id/eprint/115826

Citation Data

Cited 28 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics